Drug Profile
Research programme: nanobodies - Ablynx/Merck & Co
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Ablynx
- Class Proteins
- Mechanism of Action Immunomodulators; Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Neurological disorders